Our product pipeline covers several advanced mAb biosimilar candidates with near-term commercial visibility. 漢利康® (rituximab injection), our first product, has been granted NDA approval by the NMPA as the first biosimilar in China in February, 2019.
Leveraging the development experience of biosimilar, we are developing comprehensive bio-innovative pipeline and driving worldwide clinical studies of novel products for the long-term growth.
We have versatile in-house combination therapy portfolio with a focus on anti-PD-1/PD-L1 mAb to capture future immuno-oncology opportunities with the aim of providing affordable and effective therapies.
Fully leveraging the global research and development platform, we have developed a diversified and advanced pipeline, covering more than 20 biosimilars, and bio-innovative candidates, with significant potential for a variety of PD-1/PD-L1 based immuno-oncology combination therapies.
With a manufacturing facility established since 2016, we have passed multiple on-site inspections conducted by EU QP. The facility is in compliance with the current Good Manufacturing Practices (cGMP) standards.
We have formed a professional commercial team with rich industry experience. With the successful launch of 漢利康® (rituximab injection), we will further polish the business planning and build product marketing strategy.
In Henlius, employees are our most important resources and most valuable assets. Talents are top on our priorities.
We value talents by retaining them, developing them and putting right people to right place.